Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
107
days
Double heterozygous pathogenic germline APC and MSH2 variants in a 16-year-old female diagnosed with colorectal cancer
Authors
Elena Maccaroni; Riccardo Bacalini; Alessia Lancianese; Cecilia Copparoni; Riccardo Giampieri; Francesca Bianchi; C. Brugiati; Laura Belvederesi; Elisa Ambrosini; Natalia Chiodi; Emma Nicol Serritelli; Giulia Ricci; Valentina Tarantino; Manuela Santarosa; Francesca Morgese; Alice Magnarini; Silvia Villani; Veronica Agostinelli; Giulia Mentrasti; Alessandra Mandolesi; Gaia Goteri; Paola Coccia; Rossana BerardiShow moreShow less
Affiliations
1. Azienda Ospedaliero-Universitaria delle Marche; 2. Marche Polytechnic University; 3. Oncology Unit, "Santa Maria Della Misericordia" Hospital, 61029, Urbino, Italy; 4. Centro di Riferimento OncologicoShow moreShow less
125
days
Optimizing MRI sequences and apparent diffusion coefficient parameters for small pancreatic ductal adenocarcinoma detection
Authors
Naoko MoriShow moreShow less
Affiliations
1. Department of Radiology, Akita University Graduate School of Medicine, Akita, JapanShow moreShow less
156
days
Addressing uncertainty in hereditary colorectal cancer: the role of a regional expert multidisciplinary team meeting
Authors
Avani Varde; Terri McVeigh; Vicky Cuthill; Angela F. Brady; Bianca DeSouza; Andrew Latchford; Kevin J. MonahanShow moreShow less
Affiliations
1. The Centre for Familial Intestinal Cancer, St Mark’s The National Bowel Hospital, London, UK; 2. Surgery and Cancer, Imperial College, London, UK; 3. The Royal Marsden Hospital, London, UK; 4. North West Thames Regional Genetics Service, London, UKShow moreShow less
157
days
Healthcare provider-mediated cascade testing of Lynch syndrome to at-risk family members: an interview study
Authors
Serene Ong; Zi Yang Chua; Jeanette Yuen; Jianbang Chiang; Zhang Zewen; Joanne Ngeow; Tamra LysaghtShow moreShow less
Affiliations
1. Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; 2. Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; 3. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; 4. Sydney Health Ethics, University of Sydney, Sydney, AustraliaShow moreShow less
171
days
A novel likely pathogenic germline variant in CDKN1B in a patient with MEN4 and medullary thyroid cancer
Authors
Fernández Mercè; Queralt Asla; Francisco J. Illana; Fusté Victòria; Hernández-Losa Javier; Sesé Marta; Carmela Iglesias; Susan M. Webb; Anna AulinasShow moreShow less
Affiliations
1. Department of Endocrinology and Nutrition, Institut de Recerca Sant Pau (IR SANTPAU), Endo-ERN. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 2. Department of Endocrinology and Nutrition, Centre d’Atenció Integral Dos de Maig, Consorci Sanitari Integral, Barcelona, Spain; 3. Faculty of Medicine, University of Vic-Central University of Catalonia, Vic, Spain; 4. Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain; 5. Department of Pathological Anatomy, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6. Department of Pathological Anatomy, Vall d’Hebrón Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain; 7. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; 8. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Instituto de Salud Carlos III (ISCIII), Madrid, SpainShow moreShow less
143
days
CHEK2 -related breast cancer: real-world challenges
Authors
Luiza N. Weis; Brittany L. Bychkovsky; Adela Rodríguez Hernandez; Romualdo Barroso-Sousa; Renata L. SandovalShow moreShow less
Affiliations
1. Dasa Oncology, Hospital Brasília, Brasília, Brazil; 2. Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, USA; 3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 4. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; 5. Harvard Medical School, Boston, USA; 6. Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; 7. Department of Medicine, University of Barcelona, Barcelona, Spain; 8. Hospital Sírio-Libanês, Brasília, BrazilShow moreShow less
FAQ
How long does Familial Cancer take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for Familial Cancer. The fastest paper went from submission to acceptance in 62 days (New RPS20 gene variant in colorectal cancer diagnosis: insight from a large series of patients, received 2024-11-28, accepted 2025-01-29); the slowest took 171 days. The average is 116.1 days and the median is 125 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
